1.Immunophenotypic, cytogenetic and clinical features of 113 acute lymphoblastic leukaemia patients in China.
Haixia TONG ; Jihong ZHANG ; Chunwei LU ; Zhuogang LIU ; Yingchun ZHENG
Annals of the Academy of Medicine, Singapore 2010;39(1):49-53
<b>INTRODUCTIONb>The analysis of immunophenotype of the leukaemic cells has been of great importance for the diagnosis, classification and prognosis of acute lymphoblastic leukaemia (ALL).
<b>MATERIALS AND METHODSb>One hundred and thirteen Chinese patients with ALL were immunophenotyped by fl ow cytometry and 74 cases were also subjected to karyotype analysis by G-banding technology.
<b>RESULTSb>Of the 113 Chinese ALL patients, 14.2% were identified as T-ALL and 85.8% as B-ALL. Myeloid antigen (MyAg) expression was documented in 34.9% of the cases analysed and CD13 was most commonly expressed MyAg in ALL patients (23.6%). MyAg positivity was higher in adult with ALL (47.6%) than in children with ALL (26.6%). Abnormal karyotypes were detected in 39 out of 74 (52.7%) cases. The clinical and biological characteristics of ALL patients between MyAg+ and MyAg- groups showed that increased white blood count (WBC) (>50 x 109/L), higher CD34 positivity and higher percentage of adult patients were found to be correlated with MyAg+ ALL.
<b>CONCLUSIONb>Our results indicate that the immunophenotype did have relevance to the abnormal cytogenetic changes and clinical features in ALL. Flow cytometry immunophenotype has become the most important method for diagnosis and typing of ALL.
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; China ; epidemiology ; Cytogenetic Analysis ; Diploidy ; Female ; Humans ; Immunophenotyping ; Infant ; Male ; Middle Aged ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ; classification ; diagnosis ; genetics ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma ; classification ; diagnosis ; genetics ; Translocation, Genetic ; Young Adult
2.Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection.
Li YAO ; Zi-Xing CHEN ; Jian-Nong CEN ; Hong LIU ; Jun HE ; De-Pei WU
Chinese Journal of Hematology 2010;31(7):433-437
<b>OBJECTIVEb>To explore detection of immunoglobulin heavy chain gene (IgH) rearrangement by real-time quantitative polymerase chain reaction (RQ-PCR) for minimal residual disease (MRD) monitoring in adult B-lineage acute lymphoblastic leukemia (B-ALL) patients.
<b>METHODSb>DNA samples of fifteen newly diagnosed adult B-ALL patients were collected. The IgH gene rearrangements were detected by PCR followed by sequencing and subsequent blasting for monoclonal PCR products. Allele-specific oligonucleotides (ASO) were designed based on the sequence of junction regions, using PRIMER 5.0 software. MRD targets were detected in 115 bone marrow samples by RQ-PCR, in which ASO upstream primers in combination with the consensus JH probes and downstream primers were used. Transcripts copies of bcr-abl fusion gene were also measured in 7 Ph(+) ALL cases.
<b>RESULTSb>The detection sensitivity of ASO-PCR varied between 10(-3) and 10(-5) leukemia cells in 15 adult ALL patients. The background and nonspecific amplification was detectable at a low level. Quantification monitoring MRD showed that high-risk adult ALL patients in complete remission (CR) had a higher MRD level than those of standard-risk. Patients with MRD > 10(-3) had a higher relapse rate and a shorter survival time. Besids, the dynamic curves of the quantified level of respective IgH rearrangement were consistent with the expression levels of bcr-abl fusion genes in seven Ph(+) patients during follow-up.
<b>CONCLUSIONSb>The individual quantification of IgH rearrangement by RQ-PCR using ASO primers was a sensitive, specific and reliable method for accurate evaluation of malignant clones. These data indicates a close correlation between the level of rearranged IgH and the treatment response and prognosis in adult ALL patients. It may be a helpful method for monitoring MRD in clinical trials.
Adult ; DNA Primers ; Humans ; Immunoglobulin Heavy Chains ; genetics ; Immunoglobulins ; therapeutic use ; Neoplasm, Residual ; diagnosis ; Polymerase Chain Reaction ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ; genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; genetics
3.Research progress in Ph-like childhood acute lymphoblastic leukemia.
Chinese Journal of Contemporary Pediatrics 2017;19(11):1213-1218
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a subtype of B-lineage ALL (B-ALL) that displays a gene expression profile (GEP) similar to Philadelphia chromosome-positive ALL (PhALL). It has a diverse range of genetic alterations that activate cytokine receptor genes and kinase signaling pathways, frequently accompanied by abnormal transcription factors related to lymphatic development. Children with Ph-like ALL account for 15% of children with high-risk B-ALL. It has adverse clinical features and a poor prognosis. Tyrosine kinase inhibitors combined with chemotherapy can significantly improve the prognosis of children with PhALL, suggesting that targeted therapy based on the molecular cytogenetic abnormalities of Ph-like ALL has good research prospects. This paper expounds the genetic alterations, pathogenesis, clinical features, diagnostic measures, and potential therapeutic approaches of Ph-like childhood ALL based on recent research progress in Ph-like ALL.
Humans
;
Janus Kinase 2
;
genetics
;
PAX5 Transcription Factor
;
genetics
;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
;
diagnosis
;
drug therapy
;
genetics
;
Proto-Oncogene Proteins c-abl
;
genetics
4.Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia.
Yue-Ping JIA ; Gui-Lan LIU ; Le-Ping ZHANG
Chinese Journal of Pediatrics 2004;42(8):600-604
<b>OBJECTIVEb>The study was aimed to investigate the feasibility and clinical significance of quantitative detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) by real-time quantitative polymerase chain reaction (RQ-PCR).
<b>METHODSb>Clonal IgH gene rearrangements of samples at diagnosis were identified by standard PCR assay with consensus primers. Monoclonal IgH gene rearrangements were analyzed using DNAPLOT software. Upstream primers were designed with the Primer Express software and allele specific oligonucleotide developed complementary to the V-D or D-J junction. Samples at diagnosis were serially diluted to generate the patient specific standard curves. RQ-PCR method was used to quantify the MRD of the follow up samples collected at five time points during chemotherapy. To check the quantity and quality of DNA, the investigators used RQ-PCR analysis for the albumin gene.
<b>RESULTSb>Totally 16 monoclonal IgH gene rearrangements were identified from 34 patients with B-ALL. The analysis of the 16 monoclonal rearrangements showed that the most frequently used V segment was from V3 family and J segment from J4 and J6. The RQ-PCR sensitivity of 10(-4) to 10(-5) was mostly reached. Non-specific amplification was seen in 6 patients. The number of inserted and deleted nucleotides did not appear to be related to the sensitivity (P > 0.05). The correlation coefficients of all 16 standard curves were excellent (> or = 0.99). The mean slope of the standard curves was -3.4 +/- 0.37 and the mean intercept was 24.3 +/- 2.95. MRD analysis of follow up samples from the 16 patients showed an association between high degree of MRD and relapse. There was no apparent relationship between MRD degree at the end of induction chemotherapy and other high risk factors of ALL (P > 0.05).
<b>CONCLUSIONb>The study showed that the above approach with RQ-PCR was applicable to clinical detection of MRD in childhood ALL. Quantitative and dynamic study of MRD was of prognostic importance.
Child ; Gene Rearrangement, B-Lymphocyte ; Humans ; Neoplasm, Residual ; diagnosis ; genetics ; Polymerase Chain Reaction ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; diagnosis ; drug therapy ; genetics ; Prognosis
5.Advances in blastic plasmacytoid dendritic cell neoplasm.
Chinese Journal of Pathology 2013;42(2):131-134
CD4 Antigens
;
metabolism
;
CD56 Antigen
;
metabolism
;
Dendritic Cells
;
pathology
;
Diagnosis, Differential
;
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor
;
Hematologic Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Humans
;
Immunohistochemistry
;
Leukemia, Myeloid
;
pathology
;
Lymphoma, Extranodal NK-T-Cell
;
pathology
;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
;
pathology
;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
;
pathology
;
Skin Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
6.Correlation analysis of FPGS rs10760502G>a polymorphism with prognosis and MTX-related toxicity in pediatric B-cell acute lymphoblastic leukemia.
Shu-Guang LIU ; ; Chao GAO ; ; Zhi-Gang LI ; ; Wei-Jing LI ; ; Lei CUI ; ; Xiao-Xi ZHAO ; ; Hu-Yong ZHENG ; ; Min-Yuan WU ; ; Rui-Dong ZHANG ; ;
Journal of Experimental Hematology 2014;22(2):291-297
This study was aimed to explore the relation between folylpolyglutamate synthetase (FPGS) rs10760502 polymorphism and prognosis and methotrexate (MTX)-related toxicities in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Sequenom MassARRAY was used to genotype rs10760502. The χ(2) test, Kaplan-Meier method and Cox regression models were used to analyze the data. The results indicated that A allele carriers (GA+AA) had poor relapse free survival (RFS, log-rank: P = 0.004) and event free survival (EFS, log-rank: P = 0.022) compared with the GG genotype carriers. Multivariate Cox-regression analysis results showed that A allele is an independent prognosis factor for poor RFS [hazard ratio (HR), 20.173; 95% CI, 2.535-160.545; P = 0.005] and EFS (HR, 8.133; 95% CI, 1.718-38.512; P = 0.008). No relationship was found between any MTX toxicity and rs10760502 polymorphism. It is concluded that FPGS rs10760502G>A polymorphism may affect the treatment outcome of B-ALL patients.
Adolescent
;
Child
;
Child, Preschool
;
Female
;
Genotype
;
Humans
;
Infant
;
Leukemia, B-Cell
;
diagnosis
;
drug therapy
;
genetics
;
Male
;
Methotrexate
;
adverse effects
;
Peptide Synthases
;
genetics
;
Polymorphism, Genetic
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
genetics
;
Prognosis
7.Clinical characteristics and prognostic analysis of pediatric pro-B cell acute lymphoblastic leukemia.
Yu-Juan XUE ; Ai-Dong LU ; Yu WANG ; Yue-Ping JIA ; Ying-Xi ZUO ; Le-Ping ZHANG
Chinese Journal of Contemporary Pediatrics 2020;22(12):1286-1294
OBJECTIVE:
To explore the clinical-biological characteristics and prognosis of pediatric pro-B cell acute lymphoblastic leukemia (pro-B-ALL).
METHODS:
A total of 64 patients aged less than 18 years old with pro-BALL were enrolled. Clinical characteristics, therapeutic effect and prognostic factors were retrospectively analyzed.
RESULTS:
Pro-B-ALL occurred in 6.23% (64/1 028) of pediatric ALL. Among the 64 patients, 35 were male and 29 were female. The median age was 7.0 years (range 0.4-16.0 years) at diagnosis, of which 39% and 6% were ≥ 10 years old and < 1 year old respectively. The median WBC count was 25.5×10
CONCLUSIONS
Pediatric pro-B ALL is a heterogeneous disease with clinical and biological diversity. Biological characteristics, such as immunological markers, genetic alterations, and MRD at 3 months after chemotherapy may be important factors for the long-term prognosis.
Adolescent
;
Antigens, CD/genetics*
;
Child
;
Child, Preschool
;
Disease-Free Survival
;
Female
;
Histone-Lysine N-Methyltransferase/genetics*
;
Humans
;
Infant
;
Male
;
Myeloid-Lymphoid Leukemia Protein/genetics*
;
Neoplasm, Residual/diagnosis*
;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics*
;
Prognosis
;
Retrospective Studies
8.Acute Lymphoblastic Leukemia with Mature B-Cell Phenotype and t(9;11;11)(p22;q23;p11.2): A Case Study and Literature Review.
Borahm KIM ; Seung Tae LEE ; Hee Jin KIM ; Soo Hyun LEE ; Keon Hee YOO ; Hong Hoe KOO ; Sun Hee KIM
Annals of Laboratory Medicine 2014;34(2):166-169
No abstract available.
Aged
;
B-Lymphocytes/*cytology/metabolism
;
Child
;
*Chromosomes, Human, Pair 11
;
*Chromosomes, Human, Pair 9
;
Female
;
Humans
;
Immunophenotyping
;
Infant
;
Karyotyping
;
Male
;
Myeloid-Lymphoid Leukemia Protein/genetics/metabolism
;
Oncogene Proteins, Fusion/genetics/metabolism
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis
;
Translocation, Genetic
9.Frequency and Clinical Characteristics of Intrachromosomal Amplification of Chromosome 21 in Korean Childhood B-lineage Acute Lymphoblastic Leukemia.
Jieun KIM ; Chuhl Joo LYU ; Saeam SHIN ; Seung Tae LEE ; Jong Rak CHOI
Annals of Laboratory Medicine 2016;36(5):475-480
BACKGROUND: Intrachromosomal amplification of chromosome 21 (iAMP21) is known to be associated with poor prognosis in B-cell ALL (B-ALL). To determine the frequency and clinical characteristics of iAMP21 in Korean B-ALL patients, we performed FISH and multiplex ligation-dependent probe amplification (MLPA) analyses. METHODS: A total of 102 childhood B-ALL patients were screened with ETV6-RUNX1 FISH probes (Abbott Molecular, USA). The presence of an iAMP21 was confirmed by using MLPA P327 iAMP21-ERG probemix (MRC Holland, The Netherlands). RESULTS: iAMP21 was detected in one of the screened B-ALL patients (1/102 patients, 1.0%) who presented the ALL immunophenotype and complex karyotype at initial diagnosis. The patient relapsed twice after bone marrow transplantation. MLPA showed 12.5-Mb and 4.28-Mb regions of amplification and deletion, respectively. CONCLUSIONS: The frequency of iAMP21 is considerable in Korean pediatric patients. Our report suggests that iAMP21 in childhood B-ALL has very unfavorable impact on patient's prognosis. Additional methods such as MLPA analysis is essential to rule out patients with equivocal interphase FISH results.
Adolescent
;
Asian Continental Ancestry Group/*genetics
;
B-Lymphocytes/*metabolism
;
Child
;
Child, Preschool
;
*Chromosomes, Human, Pair 21
;
Core Binding Factor Alpha 2 Subunit/genetics
;
DNA Probes/metabolism
;
Female
;
Humans
;
Immunophenotyping
;
In Situ Hybridization, Fluorescence
;
Infant
;
Infant, Newborn
;
Male
;
Multiplex Polymerase Chain Reaction
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis/genetics
;
Proto-Oncogene Proteins c-ets/genetics
;
Repressor Proteins/genetics
;
Republic of Korea
;
Translocation, Genetic
;
Young Adult
10.A Case of Adult B Lymphoblastic Leukemia with ider(9)(q10)t(9;22)(q34;q11.2) and der(19)t(1;19)(q23;p13.3).
Soon Il JUNG ; Hee Soon CHO ; Chae Hoon LEE ; Bo Chan JUNG
The Korean Journal of Laboratory Medicine 2010;30(6):585-590
In B lymphoblastic leukemia/lymphoma (B-ALL/LBL), t(9;22)(q34;q11.2) and t(1;19)(q23;p13.3) are recurrent cytogenetic abnormalities. The concurrent occurrence of both abnormalities is very rare, and only 3 cases have been previously reported. Here, we report a case of adult B-ALL with ider(9)(q10)t(9;22)(q34;q11.2) and der(19)t(1;19)(q23;p13.3). A literature review revealed that ider(9) (q10)t(9;22) is a rare variant of t(9;22) with a deletion of the short arm of chromosome 9. Fifteen cases of ider(9)(q10)t(9;22) have been reported. This abnormality is specific to precursor B-lymphoid neoplasms, such as B-ALL or B-lymphoid blast phase of CML, and is associated with disease progression or short survival. The cytogenetic abnormality t(1;19) is also specific to B-ALL. In most instances of t(1;19), TCF3 is fused to PBX1; however, a few cases have identical translocations but no TCF3-PBX1 fusion, as was observed in our patient. We describe the first case of ider(9)(q10)t(9;22) in combination with TCF3-PBX1 negative t(1;19). The patient underwent imatinib therapy in addition to intensive chemotherapy, but failed to achieve remission.
Bone Marrow Cells/cytology/pathology
;
Chromosome Deletion
;
Chromosomes, Human, Pair 1
;
Chromosomes, Human, Pair 19
;
Chromosomes, Human, Pair 22
;
Chromosomes, Human, Pair 9
;
Female
;
Fusion Proteins, bcr-abl/genetics/metabolism
;
Humans
;
In Situ Hybridization, Fluorescence
;
Karyotyping
;
Middle Aged
;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis/genetics
;
*Translocation, Genetic